Is ZEJULA Right for You?

Whether you are considering a maintenance treatment or simply wondering what the next step will be after chemotherapy, your doctor can help you find the right choice for you.

ZEJULA may be right for you if you are a woman diagnosed with recurrent ovarian, fallopian tube, or primary peritoneal cancer that has1

  • Previously been treated with 2 or more courses of platinum-based chemotherapy, and
  • Responded (completely or partially) to the most recent treatment

ZEJULA offers more time without your cancer recurring, regardless of BRCA status1

One of the ways ZEJULA was studied was by looking at information gathered during the clinical trial about how long women lived without progression. One analysis estimated the likelihood of progression during specific time points, such as 2 years after beginning therapy. This estimated how likely it was that women participating in the study were still receiving ZEJULA or placebo at 2 years.2,3*

After 2 years of treatment with ZEJULA, it was estimated that

62 percent

of women who were BRCA-positive would not experience progression of their recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer compared with 16% who did not receive ZEJULA3

41 percent

of women who were BRCA-negative§ would not experience progression of their recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer compared with 12% who did not receive ZEJULA3

Estimated long-term PFS of 24 months.

*Patients in the study whose cancer progression status was unknown were not included in this analysis.2
Long-term information about overall survival is not yet available.2
Had an inherited mutation.
§Did not have an inherited mutation.

Talk to your doctor today


Talk to your doctor today to see if ZEJULA may be right for you. Download this Conversation Guide to help you talk with your doctor.

download now

Women with
More Time

Listen to women like you talk about their maintenance treatment with ZEJULA

See their stories

Support
During Treatment

Find resources that may help you access and pay for ZEJULA

Get Access and Support

ZEJULA
MY WAY

Get support whether you're already taking ZEJULA or still deciding if it's right for you

Sign up now

References: 1. ZEJULA [package insert]. Waltham, MA: TESARO, Inc; 2018. 2. Mirza MR, Monk BJ, Herrstedt J, et al; for the ENGOT-OV16/NOVA investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016:375(22):2154-2164. 3. Data on file. TESARO, Inc. 

Back to Top